StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Stock Performance GLMD stock opened at $0.46 on Tuesday. The firm has a market cap of $764,400.00, a price-to-earnings ratio of -0.12 and […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,Institutional Investors Weigh In On Galmed Pharmaceuticals ,Millennium Management ,Galmed Pharmaceuticals Stock Performance ,Galmed Pharmaceuticals Ltd ,Raymond James Financial Services Advisors Inc ,Walleye Capital ,News Ratings For Galmed Pharmaceuticals Daily ,Galmed Pharmaceuticals ,Cambridge Investment Research Advisors Inc ,Free Report ,Get Free Report ,James Financial Services Advisors ,Investment Research Advisors ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,